Regeneron Pharmaceuticals Inc. buy Piper Sandler
Summary
This prediction ended on 02.11.25 with a price of €568.00. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -27.20%. A total of €2.60 was paid as dividends for this prediction. Piper_Sandler has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.060% | 0.060% | -1.752% |
| iShares Core DAX® | -0.383% | 2.613% | 11.343% |
| iShares Nasdaq 100 | -0.411% | -2.005% | 5.353% |
| iShares Nikkei 225® | 1.838% | 9.391% | 33.529% |
| iShares S&P 500 | -0.712% | -0.476% | 2.508% |
Comments by Piper_Sandler for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by Piper_Sandler for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
27.01.25
27.01.26
28.01.26
Regeneron Pharmaceuticals Inc.
23.08.24
23.08.25
24.08.25

